Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Hematology ; 29(1): 2304488, 2024 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-38299685

RESUMO

OBJECTIVE: This study analyzed the relationship between bone marrow microvessel density (MVD) and the expression of four miRNAs with chronic myelogenous leukemia (CML) resistance after tyrosine kinase inhibitor (TKI) treatment. METHODS: 234 CML patients were divided into resistance and non-resistance groups in terms of the results of the 5-year follow-up. Patients were divided into the Optimum response group and the Warning/Failure group based on TKI response. MVD was determined by immunohistochemistry, and the expression levels of four miRNAs (miR-106a, miR-155, miR-146a, and miR-340) in bone marrow biopsy specimens were examined by qPCR. We evaluated the association of MVD with four miRNAs and them predictive value for CML resistance after TKI treatment. RESULTS: The MVD and the levels of miR-106a, miR-155, and miR-146a were significantly higher while the miR-340 level was lower in the resistance group than the non-resistance group. Besides, MVD had a significant correlation with the levels of miR-340 and miR-155. According to the results of survival analysis, MVD as well as miR-340 and miR-155 levels were observably correlated with 5-year survival of patients without TKI resistance. The results of the ROC curve indicated that the MVD, miR-106a, miR-340, and miR-155 had good predictive accuracy for CML resistance after TKI treatment. As for the results of multivariate analysis, disease stage, risk level (high risk), high MVD, low miR-340 expression, and high miR-155 expression were all independent risk factors for CML resistance. CONCLUSION: MVD and the expression of miR-340 and miR-155 are closely associated with CML resistance after TKI treatment.


Assuntos
Leucemia Mielogênica Crônica BCR-ABL Positiva , MicroRNAs , Humanos , MicroRNAs/genética , MicroRNAs/metabolismo , Medula Óssea/patologia , Densidade Microvascular , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Inibidores de Proteínas Quinases/farmacologia , Inibidores de Proteínas Quinases/uso terapêutico , Resistencia a Medicamentos Antineoplásicos/genética
2.
Colloids Surf B Biointerfaces ; 227: 113388, 2023 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-37285668

RESUMO

The use of medical indwelling catheters in conjunction with implantable medical devices has saved countless lives in various medical procedures. However, biofilm formation on catheter surfaces remains a persistent problem that can lead to chronic infections and device failure. Current approaches to addressing this issue involve the use of biocidal agents or self-cleaning surfaces, but these methods are limited in their effectiveness. Superwettable surfaces have shown great promise in preventing biofilm formation by manipulating the adhesive properties between bacteria and catheter surfaces. In this study, we present a novel medical indwelling catheter with hierarchically structured coatings that exhibit specific wettability and antibacterial properties. By integrating the hierarchical structure and specific wettability, we have developed an indwelling catheter with high flexibility and self-cleaning ability, which is very promising in biomedical engineering applications. Our approach draws inspiration from natural examples, such as the compound eyes of mosquitoes and lotus leaves, and represents a significant step forward in the development of effective anti-infection strategies for medical indwelling catheters.


Assuntos
Antibacterianos , Cateteres de Demora , Animais , Molhabilidade , Antibacterianos/farmacologia , Antibacterianos/química , Engenharia Biomédica , Próteses e Implantes , Biofilmes
3.
Front Genet ; 13: 804614, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35615374

RESUMO

Background: Acute myelocytic leukemia (AML) is one of the hematopoietic cancers with an unfavorable prognosis. However, the prognostic value of N 6-methyladenosine-associated long non-coding RNAs (lncRNAs) in AML remains elusive. Materials and Methods: The transcriptomic data of m6A-related lncRNAs were collected from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database. AML samples were classified into various subgroups according to the expression of m6A-related lncRNAs. The differences in terms of biological function, tumor immune microenvironment, copy number variation (CNV), and drug sensitivity in AML between distinct subgroups were investigated. Moreover, an m6A-related lncRNA prognostic model was established to evaluate the prognosis of AML patients. Results: Nine prognosis-related m6A-associated lncRNAs were selected to construct a prognosis model. The accuracy of the model was further determined by the Kaplan-Meier analysis and time-dependent receiver operating characteristic (ROC) curve. Then, AML samples were classified into high- and low-risk groups according to the median value of risk scores. Gene set enrichment analysis (GSEA) demonstrated that samples with higher risks were featured with aberrant immune-related biological processes and signaling pathways. Notably, the high-risk group was significantly correlated with an increased ImmuneScore and StromalScore, and distinct immune cell infiltration. In addition, we discovered that the high-risk group harbored higher IC50 values of multiple chemotherapeutics and small-molecule anticancer drugs, especially TW.37 and MG.132. In addition, a nomogram was depicted to assess the overall survival (OS) of AML patients. The model based on the median value of risk scores revealed reliable accuracy in predicting the prognosis and survival status. Conclusion: The present research has originated a prognostic risk model for AML according to the expression of prognostic m6A-related lncRNAs. Notably, the signature might also serve as a novel biomarker that could guide clinical applications, for example, selecting AML patients who could benefit from immunotherapy.

4.
Hematology ; 27(1): 1217-1222, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36367991

RESUMO

OBJECTIVES: This study evaluates the efficacy and safety of plasmapheresis without plasma transfusion tandem with chemotherapy in treating multiple myeloma (MM). METHOD: This retrospective study involves seventy-two patients, newly diagnosed with multiple myeloma, divided into two groups; one with plasmapheresis without plasma transfusion tandem with the chemotherapy group (Trial group), while the second was chemotherapy group (Control group). The levels of Plasma Globulin, ß2-microglobulin, Creatinine, Vascular endothelial growth factor (VEGF), and IL-6 were monitored after plasmapheresis, at initial diagnosis, and after four chemotherapy courses. Overall response rate of groups after four courses of chemotherapy was analyzed, and the adverse events were recorded. RESULTS AND DISCUSSION: The baseline data showed that sixty-seven percent of patients were at the ISS III stage and showed more severe renal insufficiency in the Trial group. The Plasma Globulin, ß2-microglobulin, VEGF and IL-6 levels were significantly different between the two groups during the initial diagnosis. After three times plasmapheresis, Plasma Globulin, ß2-microglobulin, VEGF, and IL-6 were significantly reduced in the plasmapheresis group. The Creatinine levels were also lowered, but the differences were not statistically significant. After four courses of chemotherapy, the levels of VEGF and IL-6 in the two groups were significantly reduced than the initial diagnosis; the differences were statistically considerable. No adverse events were found in the trial group as compared to the control group. CONCLUSION: Plasmapheresis reduces Globulin, ß2-microglobulin, serum VEGF and IL-6 levels in MM, improves renal functions, and releases some patients from dialysis dependence.


Assuntos
Mieloma Múltiplo , Humanos , Transfusão de Componentes Sanguíneos , Creatinina , Interleucina-6 , Mieloma Múltiplo/tratamento farmacológico , Plasma , Plasmaferese , Estudos Retrospectivos , Fator A de Crescimento do Endotélio Vascular/uso terapêutico
5.
Cancer Manag Res ; 13: 5785-5791, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34321925

RESUMO

OBJECTIVE: To evaluate the Li's and Japanese scoring methods scoring for screening early gastric cancer in a healthy population. METHODS: During January 2016-December 2018, profiles of the healthy people participated in a physical examination in the first people's Hospital of Shanghai were collected. A total of 342 volunteers, including 137 males and 205 females ageing 40-74, were enrolled. After recording the basic information, all volunteers were scored using the Japan scoring method and the new gastric cancer screening score (ie, Li's score). The subjects' work characteristics (ROC curve) were drawn according to the patient's endoscopic pathological examination to indicate early gastric cancer, to determine the best cut-off point for the diagnosis of early gastric cancer by Japanese scoring and Li's scoring, respectively. The sensitivity and specificity of both scoring methods were calculated as well. RESULTS: The area under the ROC curve of Japanese and Li's score, in the diagnosis of early gastric cancer, was 0.763 and 0.837, respectively. Japanese and Li's score ≥14 were considered as the best cut-off point. The sensitivity and specificity of Li's scoring were 63.60% and 91.10%, respectively. The sensitivity and specificity of the Japanese score were 54.50% and 87.50%, respectively. The area under the ROC curve in Li's scoring is more significant than that in Japanese scoring, and there was a substantial difference in the two methods (P<0.05). CONCLUSION: Both Li's scoring and Japanese scoring have shown good screening value for early gastric cancer in a healthy population, but Li's scoring is more sensitive/specific than Japanese scoring.

6.
Yonsei Med J ; 59(5): 643-651, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29869462

RESUMO

PURPOSE: To investigate the efficacy and safety of umbilical cord blood (UCB) infusion (UCBI) plus immunosuppressive therapy (IST) treatment in comparison to IST treatment, as well as predictive factors for clinical responses, in severe aplastic anemia (SAA) patients. MATERIALS AND METHODS: Totally, 93 patients with SAA were enrolled in this cohort study. In the IST group, rabbit antithymocyte globulin (r-ATG) combined with cyclosporine A (CsA) was administered, while in the IST+UBCI group, r-ATG, CsA, and UCB were used. RESULTS: After 6 months of treatment, UCBI+IST achieved a higher complete response (CR) rate (p=0.002) and an elevated overall response rate (ORR) (p=0.004), compared to IST. Regarding hematopoietic recovery at month 6, platelet responses in the UCBI+IST group were better than those in the IST group (p=0.002), and UCBI+IST treatment facilitated increasing trends in absolute neutrophil count (ANC) response (p=0.056). Kaplan-Meier curves illuminated UCBI+IST achieved faster ANC response (p<0.001) and platelet response (p<0.001), compared with IST therapy. There was no difference in overall survival (OS) between the two groups (p=0.620). Furthermore, logistic regression analysis demonstrated that UCBI+IST was an independent predicting factor for both CR (p=0.001) and ORR (p<0.001), compared to IST; meanwhile, very severe aplastic anemia (VSAA) and ANC could predict clinical responses as well. However, Cox proportional hazard regression indicated that VSAA (p=0.003), but not UCBI+IST, affected OS. Safety profiles showed that UCBI+IST therapy did not elevate adverse events, compared with IST treatment. CONCLUSION: UCBI+IST achieved better clinical responses and hematopoietic recovery than IST, and was well tolerated in SAA patients.


Assuntos
Anemia Aplástica/terapia , Soro Antilinfocitário/uso terapêutico , Ciclosporina/uso terapêutico , Sangue Fetal/transplante , Imunossupressores/administração & dosagem , Imunossupressores/uso terapêutico , Neutrófilos/efeitos dos fármacos , Adolescente , Adulto , Anemia Aplástica/sangue , Anemia Aplástica/tratamento farmacológico , Animais , Plaquetas , Criança , Estudos de Coortes , Feminino , Humanos , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Coelhos , Índice de Gravidade de Doença , Taxa de Sobrevida , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA